<DOC>
	<DOC>NCT00619957</DOC>
	<brief_summary>Two year study to determine the safety and efficacy of weekly 35 mg Risedronate doses in men with osteoporosis followed by a two year follow-up study.</brief_summary>
	<brief_title>Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Documented osteoporosis of the femoral neck and lumbar spine BMI greater than or equal to 35</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>